Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Protein Tyrosine Phosphatases Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Protein Tyrosine Phosphatases Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Protein Tyrosine Phosphatases (PTPs) are a superfamily with the members being regulators in multiple signal transduction pathways. PTPs catalyze the dephosphorylation of Protein Tyrosine Kinase (PTK) themselves or their downstream targets. Therefore, Protein Tyrosine Phosphorylation is a critical regulatory process responsible for regulating cell proliferation, adhesion, communication, and differentiation. These have been categorized into four types depending upon the amino acid sequence and substrate specificity, namely classical phosphorylated tyrosine (pTyr)-specific PTPs, dual-specific phosphatases (DSPs), Cdc25 phosphatase, and low molecular weight PTPs (LMW-PTPs). Classical phosphorylated tyrosine (pTyr)-specific PTPs is further categorized into intracellular and receptor-type PTPs. Proper working of the immune response is essential else the body would become a hub of many diseases. PTP dysfunction would lead to a variety of diseases like various types of cancers, Type 2 Diabetes, and Autoimmune diseases like Rheumatoid Arthritis and so clinical investigations around the globe are being conducted to study the mechanism in detail and possible treatment that could be used in case of their dysfunction. Extensive research is being conducted globally to discover new and novel molecules to be used as Protein Tyrosine Phosphatase, like Suramin, is used for the treatment of African Sleeping Sickness. The development and launch of new products will thus increase the market’s revenue in the forecasted years. According to the WHO 2023 report, an estimated 700,000 to 1 million new cases are reported annually, with about 85% of all Cutaneous Leishmania occurring in America, the Mediterranean basin, the Middle East, and central Asia. Due to the poor hygienic conditions of these regions and the increasing prevalence of other indications, there is an excellent market for the global players ahead.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 47 products in different stages of clinical trials - 3 in Phase 3, 12 in Phase 2, and 15 in Phase 1 of the clinical trials.
Drugs in the Pipeline of Protein Tyrosine Phosphatase
Clinical Activity and Developments of Protein Tyrosine Phosphatase
As of July 2023, various companies have approximately 47 products for 137 diseases. For these diseases, many trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Germanin (suramin) |
20 |
|
Lenocta (sodium stibogluconate) |
20 |
|
batoprotafib (TNO155) |
9 |
|
vociprotafib (RMC-4630) |
6 |
|
ISIS 113715 |
5 |
Protein Tyrosine Phosphatase plays a significant role in regulating major signal transduction pathways. Dysfunctional PTPs have been associated with many diseases like cancers, Type 2 Diabetes, Autoimmune diseases, and Neurological disorders. Drugs acting upon the PTP pathway are being evaluated in many clinical trials globally for many illnesses. Drugs like Suramin are being used to treat various diseases like African Sleeping Sickness (African Trypanosomiasis), River Blindness (Onchocerciasis), and other infectious diseases. Suramin has also shown potent anti-neoplastic properties. Therefore, drugs affecting the PTP mechanism are in the clinical trials for the treatment of various diseases like Adenocarcinoma, Male Genital Disease, Visceral and Cutaneous Leishmaniasis, Parasitic and Protozoal infections, Urogenital neoplasms, and many others.
According to the American Society of Clinical Oncology 2023 report, Prostate cancer is the 2nd most common cancer in men, with an estimated 288,300 men expected to be diagnosed with it in the USA. In 2020, about 1,414,259 people were diagnosed with it globally, making it the 4th most commonly diagnosed cancer globally. It is more common in men aged 60 and above, with 60% of cases from them. According to a 2023 research report, Lung Adenocarcinoma is estimated to be around 40% of the lung cancers in the USA, more prevalent amongst the population who had never smoked owing to the increased pollution and suspended particulate matter in the air that is constantly irritating the lung mucosa and causing a chronic inflammatory situation that is leading towards lung cancer. The prevalence rate of the diseases is on the rising trend marking an opportunity for global players to enter new markets with innovative approved products.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Currently, no drugs in this category are approved by any regulatory agencies.
Suramin has been used to treat African Sleeping Sickness (African Trypanosomiasis) and River Blindness (Onchocerciasis). Other indications are Adenocarcinoma, Male Genital Disease, Visceral and Cutaneous Leishmaniasis, Parasitic and Protozoal infections, Urogenital neoplasms, and many others.
Optimum Therapeutics, VioQuest Pharmaceuticals, Novartis AG, Revolution Medicines, and Ionis Pharmaceuticals are some of the major market players for Protein Tyrosine Phosphatase.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market, and rising incidence of various types of conditions like African Trypanosomiasis, Onchocerciasis, Visceral, and Cutaneous Leishmaniasis and others are the key opportunities for Protein Tyrosine Phosphatase in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.